Neurocrine Biosciences (NBIX) total assets

Total assets · fiscal 2025
$4.63B

Neurocrine Biosciences (NBIX) had total assets of $4.63B at the end of fiscal 2025 (December 31, 2025). That is 24.5% higher than the $3.72B of fiscal 2024. Figures as of 18 Nov 2026, 10:31 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total assets, fiscal 2025
$4.63B
Change on fiscal 2024
+24.5%
Growth, 5 years
+21.7% a year
Growth, 10 years
+25.6% a year
Highest on record
$4.63Bfiscal 2025
Lowest on record
$138.37Mfiscal 2011
Fiscal years on record
162010–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Neurocrine Biosciences total assets, in more detail

Over the five fiscal years to 2025 total assets grew at a compound 21.7% a year; over ten years the rate was 25.6% a year. Across the 16 fiscal years on record (2010–2025), the highest was $4.63B in fiscal 2025 and the lowest $138.37M in fiscal 2011.

History · 16 fiscal years

Total assets by fiscal year

Neurocrine Biosciences total assets, year by year

Neurocrine Biosciences (NBIX) total assets by fiscal year
Fiscal yearTotal assetsChangeYear ended
2025$4.63B 24.5% up
2024$3.72B 14.4% up
2023$3.25B 37.3% up
2022$2.37B 14.3% up
2021$2.07B 19.5% up
2020$1.73B 32.8% up
2019$1.31B 31.5% up
2018$993.15M 21.5% up
2017$817.59M 123.9% up
2016$365.09M 23.1% down
2015$474.79M 95.4% up
2014$243.03M 57.1% up
2013$154.68M 21.1% down
2012$195.98M 41.6% up
2011$138.37M 4.2% down
2010$144.42M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total assets is everything on the balance sheet at the fiscal year-end — cash, receivables, inventory, property, goodwill and the rest.

How to read it

It measures the resources the business has put to work; assets that grow faster than profit mean each new unit of investment is earning less.

Total assets at health care companies of similar size

Total assets of Neurocrine Biosciences and comparable companies
CompanyTotal assetsFiscal year
Exelixis EXEL$2.84B2025
Neurocrine Biosciences NBIX$4.63B2025
Ascendis Pharma ASND€1.30B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on NBIX

Neurocrine Biosciences, figure by figure

Neurocrine Biosciences (NBIX) overview: price, valuation and scorecardAll health care companies by market value

Neurocrine Biosciences total assets: questions and answers

How large are Neurocrine Biosciences's total assets?

Neurocrine Biosciences (NBIX) had total assets of $4.63B at the end of fiscal 2025 (December 31, 2025). That is 24.5% higher than the $3.72B of fiscal 2024.

What is the growth rate of Neurocrine Biosciences's total assets?

Over the five fiscal years to 2025 total assets grew at a compound 21.7% a year; over ten years the rate was 25.6% a year.

What are the highest and lowest total assets figures on record for Neurocrine Biosciences?

Across the 16 fiscal years on record (2010–2025), the highest was $4.63B in fiscal 2025 and the lowest $138.37M in fiscal 2011.

How is Neurocrine Biosciences's total assets calculated?

Total assets is everything on the balance sheet at the fiscal year-end — cash, receivables, inventory, property, goodwill and the rest. For Neurocrine Biosciences it is on record here for 16 fiscal years, 2010 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Neurocrine Biosciences (NBIX) total assets”, data as of 18 November 2026. https://funkfolio.com/stock/NBIX/total-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.